Yes it was a good find. But with them doing their own trials this will suck a lot of cash going forward with no promise of a approved drug. The lack of clarity this company has continually refused to have on any FDA approval of their generic Copaxone, and continued insider sales(albeit small) still raise doubt that this can be a long lived company, unless they think about dilution and a share offering the May dates have come and gone ,and the FDA after 6 years has not given any approval.
duude!... there is a distinction between "Designated" and "Approved"... one implies the beginning of clinical trials and the other the end... designated, necuparanib will qualify for incentives from the FDA as it goes to trials... aloha K